CAR T-Cells: Treatment Overview, Toxicity Management, and Administration Considerations is organized by Infusion Nurses Society (INS).
Expiration date for receipt of contact hours: November 14, 2021
This session has been approved for 1 contact hour
CRNI® RUs: This session has been approved for 1 CRNI® recertification unit and meets the non INS Meeting criteria.
Chimeric antigen receptor (CAR) T-cells are cellular immunotherapies used for the treatment of some malignancies. This adoptive cell therapy represents a new paradigm in cancer treatment, one in which the patient’s own immune system, specifically T-cells, are engineered to treat his or her cancer. CAR T-cell therapy is a complex treatment associated with unique and serious toxicities, making education a necessity for both the patient and the health care provider. This presentation will provide an overview of CAR T-cell therapy, toxicity assessment and management strategies, administration considerations, and patient education needs for the health care provider.
At the end of this educational activity, learners will be able to:
• Describe the mechanism of action for CAR T-cells
• Identify 3 common toxicities associated with CAR T-cells, as well as associated management strategies
• Verbalize administration considerations for CAR T-cell products
Additional details will be posted as soon as they are available.
Toxicology, Oncology, Immunotherapies